Evidence map›Paper›PMID 29511352›Full record

ArticleOncogene2018

Regulation of inside-out β1-integrin activation by CDCP1.

Sara G Pollan, Fangjin Huang, Jamie M Sperger, Joshua M Lang, Colm Morrissey, Anne E Cress, C Y Chu, Neil A Bhowmick, Sungyong You, Michael R Freeman and 6 more

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Extracellular matrix and its therapeutic potential for cancer treatment.Signal transduction and targeted therapy · 2021
    Review
  6. Loss of CDCP1 triggers FAK activation in detached prostate cancer cells.American journal of clinical and experimental urology · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Sara G PollanCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Fangjin HuangCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Jamie M SpergerUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, 53705, USA.
Joshua M LangUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, 53705, USA.
Colm MorrisseyUniversity of Washington, Seattle, WA, 98195, USA.
Anne E CressUniversity of Arizona Cancer Center, Tucson, AZ, 85704, USA.
C Y ChuCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Neil A BhowmickCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Sungyong YouCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.ORCID http://orcid.org/0000-0003-3513-1783
Michael R FreemanCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Danislav S SpassovUniversity of California San Francisco, San Francisco, CA, 94143, USA.
Mark M MoasserUniversity of California San Francisco, San Francisco, CA, 94143, USA.
William G CarterFred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.
Shakti Ranjan SatapathyPurdue University, West Lafayette, IN, 47907, USA.
Kavita ShahPurdue University, West Lafayette, IN, 47907, USA.ORCID http://orcid.org/0000-0002-0451-1305
Beatrice S KnudsenCedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Beatrice.Knudsen@cshs.org.
Cedars-Sinai Medical Center · USPurdue University West Lafayette · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · USFred Hutch Cancer Center · USUniversity of Arizona · USUniversity of Washington · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Human Prostate Cancer Metastasis and Laminin Binding IntegrinsR01CA159406 · NCI · UNIVERSITY OF ARIZONA · PI CRESS, ANNE E · 2011 to 2015
$1.5M
Chemical Genetic Dissection of Aurora A in Promoting EMT and Stem Cells PhenotypeR03CA166912 · NCI · PURDUE UNIVERSITY · PI SHAH, KAVITA · 2013 to 2014
$152k
NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA159406NCI NIH HHS R03 CA166912
6 · The paper itself

Abstract

Tumor metastasis depends on the dynamic regulation of cell adhesion through β1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. Here, we demonstrate reduced CDCP1 expression in high-grade, primary prostate cancers, circulating tumor cells and tumor metastases of patients with castrate-resistant prostate cancer. CDCP1 is expressed in epithelial and not mesenchymal cells, and its cell surface and mRNA expression declines upon stimulation with TGFβ1 and epithelial-to-mesenchymal transition. Silencing of CDCP1 in DU145 and PC3 cells resulted in 3.4-fold higher proliferation of non-adherent cells and 4.4-fold greater anchorage independent growth. CDCP1-silenced tumors grew in 100% of mice, compared to 30% growth of CDCP1-expressing tumors. After CDCP1 silencing, cell adhesion and migration diminished 2.1-fold, caused by loss of inside-out activation of β1-integrin. We determined that the loss of CDCP1 reduces CDK5 kinase activity due to the phosphorylation of its regulatory subunit, CDK5R1/p35, by c-SRC on Y234. This generates a binding site for the C2 domain of PKCδ, which in turn phosphorylates CDK5 on T77. The resulting dissociation of the CDK5R1/CDK5 complex abolishes the activity of CDK5. Mutations of CDK5-T77 and CDK5R1-Y234 phosphorylation sites re-establish the CDK5/CDKR1 complex and the inside-out activity of β1-integrin. Altogether, we discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates β1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer.

Indexed as

Down-RegulationAnimalsAntigens, CDAntigens, NeoplasmCell Adhesion MoleculesCell Line, TumorCell MovementCell ProliferationCyclin-Dependent Kinase 5Epithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansIntegrin beta1MaleMiceNeoplasm GradingAntigens, CDAntigens, NeoplasmCDCP1 protein, humanCDK5 protein, humanCell Adhesion MoleculesCyclin-Dependent Kinase 5Integrin beta1Neoplasm Proteins

Identifiers

PMID29511352
PMCPMC6824599
OpenAlexW2793646633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.